🔗 Share this article

A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, based on recent findings.

Investigational Drug Gaining Traction Online

Retatrutide, which is still in research studies, is being promoted by online personalities for its supposed fat-burning properties. Followers are urged to contact these accounts privately for source information, while also obtaining promotional offers.

Thriving Trade on Social Networks

Separately, a robust trade exists on Telegram, where groups with thousands of members share “before and after” photos, injection guides and assertions of next-day British shipping. Vendors promote the drug there before directing customers to WhatsApp for transactions.

Understanding Retatrutide

This medication is an experimental injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could assist patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Medical Experts Express Worries

Nevertheless, doctors and chemists have cautions that the sale of what remains an unlicensed drug in the UK is a cause for concern and could lead to users administering substances of unknown origin.

Some experts said the demand for the experimental drug could be linked to the increasing price of approved weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Selling retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some influencers attempt to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still violate pharmaceutical, advertising, and customer regulations, risking fines, prosecution or prison.

Service Reaction and Content Elimination

Based on the social media company, the platform has removed violative content and banned related hashtags and search suggestions. The organization said it was dedicated to maintaining the service safe and allocating resources in enhancing compliance measures.

Online Trading Activities

Investigations also found groups with up to 9,000 participants selling retatrutide using the platform's integrated search feature, which functions like a public directory. Entering “retatrutide” instantly brings up groups with numerous of users, populated with images of weight loss, glowing testimonials and step-by-step guides for mixing or administering at residence.

After minutes of entering one group, a seller posted WhatsApp details, where most purchases occur. The vendor provided an instruction manual and promised delivery within two days. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed testing documentation. Not one asked about weight, health issues or previous experience.

Product Details and Costs

Within these groups, posts display black plastic parcels with postal service labels, stating to include new batches. One message stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at residence with sterile water, or ready-to-use injectors typically priced at 160 pounds for 20 milligrams. When asked how long a pen should last, sellers give conflicting answers varying between a several days to “depends on your body”.

Service Moderation and Security Actions

A spokesperson for Telegram stated it regularly monitored dangerous content on its service including content that encouraged the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“Individuals are injecting substances they cannot confirm. Although the research behind this drug is sound, these digital versions may not contain what they advertise,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of an online medical service connected the surge in interest to recent price rises for authorized weight-loss medications such as Mounjaro. “With costs rising, individuals are using social media. But fake treatments are extremely risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has already seen individuals injured by self-injection from unverified sources. “We recognize the disappointment, but buying from Telegram or communication platforms is gambling with your well-being,” stated Wyllie. “These substances could be impure or improperly measured.”

Producer Position

A representative from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority globally. “Consequently at this point no one can market [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a company experimental product not yet approved … may subject patients to potentially serious medical dangers”.